Neulasta

Coherus cuts staff after FDA red light
Coherus cuts staff after FDA red light
BioPharma Dive
Coherus Biosciences
layoffs
FDA
biosimilars
Amgen
Neulasta
Flag link:
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Endpoints
Amgen
Novartis
Supreme Court
biosimilars
Neulasta
FDA
Coherus Biosciences
Flag link:
Amgen accuses would-be copycat Coherus of stealing its Neulasta secrets
Amgen accuses would-be copycat Coherus of stealing its Neulasta secrets
Fierce Pharma
Coherus Biosciences
Amgen
Neulasta
biosimilars
Flag link:
Novartis silently yanks a troubled biosimilar application; Chinese antibody developer draws $39M round
Novartis silently yanks a troubled biosimilar application; Chinese antibody developer draws $39M round
Endpoints
Novartis
biosimilars
Zioxtenzo
Europe
Amgen
Neulasta
China
Flag link:
Amgen Products Threatened by Court Losses
Amgen Products Threatened by Court Losses
Investopedia
Amgen
Apobiologix
Neupogen
Grastofil
Neulasta
Lapelga
biosimilars
patents
Flag link:
U.S. FDA knocks back Novartis copy of Amgen's drug Neulasta
U.S. FDA knocks back Novartis copy of Amgen's drug Neulasta
Yahoo/Reuters
FDA
Novartis
biosimilars
Amgen
Neulasta
Flag link:
EU agency accepts Sandoz application for pegfilgrastim biosimilar
EU agency accepts Sandoz application for pegfilgrastim biosimilar
Yahoo/Reuters
Europe
Sandoz
Novartis
biosimilars
pegfilgrastim
Neulasta
Flag link:
Amgen stalls Apotex's Neulasta biosim launch with court victory
Amgen stalls Apotex's Neulasta biosim launch with court victory
Fierce Pharma
Amgen
Apotex
Neulasta
biosimilars
Flag link:
Novartis: Study shows copycat works just as well as Amgen drug
Novartis: Study shows copycat works just as well as Amgen drug
Yahoo/Reuters
Novartis
Amgen
Neulasta
Sandoz
generics
breast cancer
Flag link:
Novartis biosimilar takes aim at Amgen drug Neulasta
Novartis biosimilar takes aim at Amgen drug Neulasta
Yahoo/Reuters
Novartis
Amgen
biosimilars
Neulasta
Sandoz
Flag link:
Amgen: Time is on My Side
Amgen: Time is on My Side
Barron's
Amgen
Coherus Biosciences
FDA
Neulasta
Apotex
Flag link:
You’re Better Than My Last Dance Partner But Still Not Perfect: Amgen Alleges that an Otherwise Complete Patent Dance Was Ruined by Pre-Approval Notice of Marketing
You’re Better Than My Last Dance Partner But Still Not Perfect: Amgen Alleges that an Otherwise Complete Patent Dance Was Ruined by Pre-Approval Notice of Marketing
FDA Law Blog
FDA
Amgen
Neulasta
Apotex
biogenerics
patents
Flag link:
Amgen: What If Generic Neulasta Gets Delayed Until Next Year?
Amgen: What If Generic Neulasta Gets Delayed Until Next Year?
Barron's
Neulasta
generics
Amgen
Apex Labs
biosimilars
Flag link:
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar
Fierce Pharma Marketing
biosimilars
AbbVie
Roche
Amgen
Rituxan
Herceptin
Avastin
Neupogen
Neulasta
Epogen
Humira
Perjeta
Gazyva
Flag link:
The top 10 patent losses of 2015
The top 10 patent losses of 2015
Fierce Pharma
patents
Lantus
Abilify
Copaxone
Neulasta
Tracleer
Namenda
Avodart
Jalyn
Zyvox
Androgel
Synagis
Sanofi
Bristol-Myers Squibb
Otsuka
Teva Pharmaceutical
Amgen
Actelion
Actavis
GSK
Pfizer
AbbVie
AstraZeneca
Flag link:
Amgen's Neulasta Succeeds in Phase 3 Cancer Trial
Amgen's Neulasta Succeeds in Phase 3 Cancer Trial
Motley Fool
Amgen
Neulasta
colorectal cancer
Flag link:
Amgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta In Patients With Colorectal Cancer
Amgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta In Patients With Colorectal Cancer
Yahoo/PR Newswire
Amgen
Neulasta
colorectal cancer
colon cancer
Flag link:
No Drug Can Cure the Health-Care Reform Infection
No Drug Can Cure the Health-Care Reform Infection
Motley Fool
Enbrel
Pfizer
healthcare reform
earnings
Neulasta
Amgen
Neupogen
Humira
Abbott Laboratories
Remicade
Merck
JNJ
Flag link: